Nordhealth AS provides healthcare software solutions in Norway, Finland, Sweden, the United Kingdom, Denmark, DACH, and internationally. Its products include Provet, a practice management software platform for veterinary clinics and enterprise groups, providing appointment scheduling, patient management, electronic health records, billing and invoicing, reporting and analytics, government compliance tools, communication features, inventory management, and workflow automation; Diarium, a PMS for therapists that streamlines therapy sessions, booking, and invoicing; Physica, a PMS for physiotherapists; Psykbase, a PMS for psychologists and psychiatrists; EasyPractice, a PMS for therapists; and various PMS for veterinarians under the Vetserve, Sanimalis, Vetvision, and Vetera names. The company's products comprise Nordhealth Connect, a communication platform for patients and healthcare professionals; and Navisec, a digital learning environment for training and orientation. In addition, it offers services related to the implementation of SaaS systems, such as consultancy services, education, and data conversion. Further, the company provides nordhealth.fi, a consumer booking portal. Nordhealth AS was founded in 2001 and is based in Oslo, Norway.…
Nordhealth AS (OSL:NORDH) (Q3 2026) Earnings Call Highlights: 43% ARR CAGR, Margin Pressures ...
Nordhealth (OSL: NORDH) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 400 employees.
The shares were at 26.80 NOK on 19 November 2026, down 24.7% over 52 weeks. Its 52-week range is 21.20 NOK to 38.40 NOK: the price is 30.2% below the high and 26.4% above the low.
Its market capitalisation is 2.11B NOK.
Nordhealth reports return on equity of -20.6%, an operating margin of -26.6% and revenue up 17.5% year over year.
It holds more cash than debt, a net cash position of 11.58M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 35.30 NOK is 31.7% above the current price. The next earnings report is expected on 2 March 2027.